{"id":858,"date":"2021-02-19T11:21:19","date_gmt":"2021-02-19T11:21:19","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=858"},"modified":"2021-02-19T11:21:19","modified_gmt":"2021-02-19T11:21:19","slug":"17-feb-2021-anakinra-not-useful-to-improve-the-prognosis-of-patients-with-tocilizumab-refractory-severe-covid-19","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-feb-2021-anakinra-not-useful-to-improve-the-prognosis-of-patients-with-tocilizumab-refractory-severe-covid-19\/","title":{"rendered":"(17 Feb 2021) Anakinra-not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1016\/j.ijid.2021.02.041<\/p>\n<p class=\"\">A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2\/FiO2) ratio at baseline and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a six-point ordinal scale, from baseline to day 21. The study included 20 cases and 20 controls (mean age 65.3+\/-12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. In-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P=0.527). Treatment with anakinra was not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study https:\/\/doi.org\/10.1016\/j.ijid.2021.02.041 A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selected controls in a&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-feb-2021-anakinra-not-useful-to-improve-the-prognosis-of-patients-with-tocilizumab-refractory-severe-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 Feb 2021) Anakinra-not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[56,4],"tags":[57],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/858"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=858"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/858\/revisions"}],"predecessor-version":[{"id":859,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/858\/revisions\/859"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}